Normal INR Without Anticoagulation
The normal INR in a person not taking warfarin or heparin is approximately 1.0, with an acceptable reference range typically between 0.8 and 1.2.
Understanding the INR in Non-Anticoagulated Patients
The INR was specifically designed and validated only for monitoring vitamin K antagonist (VKA) therapy, not as a general screening tool for coagulopathy 1. The standardization process that created the INR relied on plasma samples from patients on stable warfarin therapy, explicitly excluding those with underlying bleeding disorders, acute illness, or liver disease 1.
Key Clinical Context
The INR has no validated role in predicting bleeding risk or assessing coagulation status in patients not taking warfarin 1. Despite widespread misuse in clinical practice, there is no high-quality evidence that INR values in the 1.0-2.0 range predict bleeding in non-anticoagulated patients 1.
Critical Pitfalls to Avoid
Do not use mildly elevated INR (1.0-2.0) as an indication for plasma transfusion in non-anticoagulated patients - this practice lacks biological plausibility and evidence of benefit, while exposing patients to transfusion risks 1
Do not rely on "normal" INR to rule out bleeding disorders - the INR has poor sensitivity for inherited or acquired coagulopathies in patients not on VKA therapy 1
Do not apply INR targets from warfarin studies to other clinical contexts such as:
When INR Monitoring Is Appropriate
INR monitoring is validated and clinically useful only in these specific contexts:
Warfarin therapy monitoring - target ranges vary by indication (typically 2.0-3.0 for most indications, 2.5-3.5 for mechanical heart valves) 2
Not validated for: general coagulopathy screening, procedural bleeding prediction, or disease severity assessment in non-anticoagulated patients 1
The widespread ordering of INR outside its validated indication represents a fundamental misunderstanding of the test's design and drives unnecessary interventions without improving patient outcomes 1.